Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer

European Journal of Cancer

Volumn 42, Issue 7, 2006, Pages 958-963

  Santos, Alexandra M ^a   Sousa, Hugo ^a   Pinto, Daniela ^a   Portela, Catarina ^a   Pereira, Deolinda ^a   Catarino, Raquel ^a   Duarte, Isabel ^a   Lopes, Carlos ^a   Medeiros, Rui ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cervical cancer; Ovarian cancer; p21; P21 3 UTR polymorphism; p53; TP53 codon 72 polymorphism

Indexed keywords

PROTEIN P21; PROTEIN P53;

3' UNTRANSLATED REGION; ADULT; ADVANCED CANCER; ALLELE; ARTICLE; CANCER RISK; CARCINOGENESIS; CODON; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HISTOPATHOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CANCER;

CASE-CONTROL STUDIES; CODON; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; LINKAGE (GENETICS); MIDDLE AGED; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 33646172093     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.015     Document Type: Article

References (30)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics 2002. CA Cancer J Clin 55 (2005) 74-108
2. Pinheiro P.S., Tyczynski J.E., Bray F., Amado J., Matos E., and Parkin D.M. Cancer incidence and mortality in Portugal. Eur J Cancer 39 (2003) 2507-2520
3. Franco E.L., Rohan T.E., and Villa L.L. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91 (1999) 506-511
4. Medeiros R., Prazeres H., Pinto D., et al. Characterization of HPV genotype profile in squamous cervical lesions in Portugal, a southern European population at high risk of cervical cancer. Eur J Cancer Prev 14 5 (2005) 467-471
5. Medeiros R., Pereira D., Afonso N., et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8 3 (2003) 156-161
6. Santos A.M., Sousa H., Catarino R., et al. TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. Cancer Genet Cytogenet 159 2 (2005) 143-147
7. Sousa H, Santos AM, Catarino R, et al. Linkage of TP53 codon 72 pro/pro genotype as predictive factors for nasopharyngeal carcinoma development. Eur J Cancer Prev 2005 [in press].
8. Pinto D., Pereira D., Portela C., da Silva J.L., Lopes C., and Medeiros R. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun 335 4 (2005) 1173-1178
9. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 5015 (1991) 49-53 [Review]
10. Terauchi F., Okamoto A., Nagashima T., et al. Clinical significance of p21 (WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. Oncol Rep 14 2 (2005) 363-368
11. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 3 (1997) 323-331 [Review]
12. Scheffner M., Huibregste J.M., Vierstra R.D., and Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitinprotein ligase in the ubiquitination of p53. Cell 75 (1993) 495-505
13. Pillai M.R., Sreevidya S., Pollock B.H., Jayaprakash P.G., and Herman B. Polymorphism at codon 72 of p53, human papillomavirus, and cervical cancer in South India. J Cancer Res Clin Oncol 128 (2002) 627-631
14. Storey A., Thomas M., Kalita A., et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393 6682 (1998) 229-234
15. Koushik A., Platt R.W., and Franco E.L. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 13 1 (2004) 11-22 [Review]
16. Tenti P., Vesentini N., Spaudo M., et al. P53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from Northern Italy. Cancer Epidemiol Biomarkers Prev 9 (2000) 435-438
17. Wang Y., Kringen P., Kristensen G.B., et al. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24 (2004) 21-34
18. Hogdall E.V., Hogdall C.K., Christensen L., et al. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res 22 3 (2002) 1859-1864
19. Agorastos T., Masouridou S., Lambropoulos A.F., et al. P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 13 4 (2004) 277-280
20. Rastinejad F., Conboy M.J., Rando T.A., and Blau H.M. Tumor suppression by RNA from the 3′ untranslated region of alpha-tropomyosin. Cell 75 6 (1993) 1107-1117
21. Fan H., Villegas C., Huang A., and Wright J.A. Suppression of malignancy by the 3′ untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs. Cancer Res 56 19 (1996) 4366-4369
22. Facher E.A., Becich M.J., Deka A., and Law J.C. Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer 79 12 (1997) 2424-2429
23. Law J.C., and Deka A. Identification of a PstI polymorphism in the p21Cip1/Waf1 cyclin-dependent kinase inhibitor gene. Hum Genet 95 4 (1995) 459-460
24. Milner B.J., Hosking L., Sun S., Haites N.E., and Foulkes W.D. Polymorphisms in P21CIP1/WAF1 are not correlated with TP53 status in sporadic ovarian tumours. Eur J Cancer 32A 13 (1996) 2360-2363
25. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 3 (1988) 1215
26. Pim D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108 2 (2004) 196-199
27. Buller R.E., Sood A., Fullenkamp C., Sorosky J., Powills K., and Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 4 4 (1997) 239-245
28. Mousses S., Ozcelik H., Lee P.D., Malkin D., Bull S.B., and Andrulis I.L. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 4 6 (1995) 1089-1092
29. Spurdle A.B., Purdie D.M., Chen X., and Chenevix-Trench G. The prohibitin 3′ untranslated region polymorphism is not associated with risk of ovarian cancer. Gynecol Oncol 90 1 (2003) 145-149
30. Koushik A., Ghosh A., Duarte-Franco E., et al. The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detect Prev 29 4 (2005) 307-316